Reviews in Urology | |
Intracavitary Immunotherapy and Chemotherapy for Upper Urinary Tract Cancer: Current Evidence | |
Elena Tondelli1  Augusto Maggioni5  Angelica Grasso5  Gabriele Cozzi5  Roberto Bianchi3  Nicola Macchione2  Carlo Marenghi4  Sara Melegari3  Marco Rosso5  Luca Carmignani4  | |
[1] Università degli Studi di Milano, Urology Department, IRCCS S. Giuseppe Hospital, Milan, Italy;Università degli Studi di Milano, Urology Department, S. Paolo Hospital, Milan, Italy;Università degli Studi di Milano, Urology Department, European Institute of Oncology, Milan, Italy;Università degli Studi di Milano, Urology Department, IRCCS Policlinico San Donato,, San Donato Milanese, Italy;Università degli Studi di Milano, Urology Department, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy | |
关键词: Upper urinary tract; Urothelial cell carcinoma; Bacillus Calmette-Guérin; Mitomycin C; Chemotherapy; Immunotherapy; | |
DOI : | |
学科分类:基础医学 | |
来源: MedReviews, LLC | |
【 摘 要 】
A review of the literature was performed to summarize current evidence regarding the efficacy of topical immunotherapy and chemotherapy for upper urinary tract urothelial cell carcinoma (UUT-UCC) in terms of post-treatment recurrence rates. A Medline database literature search was performed in March 2012 using the terms upper urinary tract, urothelial cancer, bacillus Calmette-Guérin (BCG), and mitomycin C. A total of 22 full-text articles were assessed for eligibility, and 19 studies reporting the outcomes of patients who underwent immunotherapy or chemotherapy with curative or adjuvant intent for UUT-UCC were chosen for quantitative analysis. Overall, the role of immunotherapy and chemotherapy for UUT-UCC is not firmly established. The most established practice is the treatment of carcinoma in situ (CIS) with BCG, even if a significant advantage has not yet been proven. The use of BCG as adjuvant therapy after complete resection of papillary UUT-UCC has been studied less extensively, even if recurrence rates are not significantly different than after the treatment of CIS. Only a few reports describe the use of mitomycin C, making it difficult to obtain significant evidence.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912040560438ZK.pdf | 214KB | download |